Myasthenia gravis is a disorder of neuromuscular transmission resulting from binding of autoantibodies to various components of the neuromuscular junction. In this journal club session, I will review recent studies evaluating potentially pathogenic autoantibodies in patients with seronegative myasthenia gravis (i.e., those without acetylcholine receptor or muscle-specific kinase autoantibodies). I will also review several recent prospective randomized trials evaluating the role of thymectomy and immunosuppressant therapies in the treatment of myasthenia gravis.
Date
2017
Language
eng
Format
video/mp4
Source
2017 North American Neuro-Ophthalmology Society Annual Meeting
